Terminated PHASE1 INTERVENTIONAL 2-arm NCT01434849

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial) (TiPPIH)

Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma

Sponsor: Alice K. Gong

Conditions Infantile Hemangioma Very Low Birth Weight Infants

Interventions Control (placebo) group topical 0.5% Timolol maleate

Updated 5 times since 2017 Last updated: Nov 14, 2016 Started: Jul 31, 2012 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty with enrolled patients to complete trial.

Other Infantile Hemangioma trials with similar outcome

NCT05479123 · Phase PHASE4 · Jul 2025

Browse all Infantile Hemangioma trials

This PHASE1 trial investigates Infantile Hemangioma and Very Low Birth Weight Infants and is currently terminated or withdrawn. Alice K. Gong leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alice K. Gong

Data source: The University of Texas Health Science Center at San Antonio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States